Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMI0CYV)

• Drug Name: RG-8803 Drug Info
• Synonyms: Angiogenesis inhibitors, Repligen; BFGF inhibitors, Repligen; RG-8803B11; RGEN-1009; VEGF inhibitors, Repligen; 8803B11

Indication

Disease Entry	ICD 11	Status	REF
Diabetic retinopathy	9B71.0	Terminated	[1]

• Cross-matching ID: TTD Drug ID: DMI0CYV

Molecule-Related Drug Atlas

Drug(s) Targeting Fibroblast growth factor-2 (FGF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sucralfate	DMP9HBO	Acne vulgaris	ED80	Approved	[3]
Squalamine	DM3PS2E	Solid tumour/cancer	2A00-2F9Z	Phase 3	[4]
DVC1-0101	DMUGBQK	Arteriosclerosis	BD40	Phase 2	[5]
Bemarituzumab	DMWNYIE	Gastric adenocarcinoma	2B72	Phase 2	[6]
FPA144	DM1EBRK	Bladder cancer	2C94	Phase 1	[7]
TGP-580	DMYN6G0	Neurodegenerative disorder	8A20-8A23	Discontinued in Phase 2	[8]
2-Sulfhydryl-Ethanol	DMJBO3D	Discovery agent	N.A.	Investigative	[9]
N,O6-Disulfo-Glucosamine	DMYCV7U	Discovery agent	N.A.	Investigative	[9]
BIBF100	DMUWO6D	Multiple myeloma	2A83	Investigative	[10]
1,4-Dideoxy-O2-Sulfo-Glucuronic Acid	DM9KUQZ	Discovery agent	N.A.	Investigative	[9]

Drug(s) Targeting Vascular endothelial growth factor receptor (VEGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[11]
Fruquintinib	DMHOSCQ	Colorectal cancer	2B91.Z	Approved	[6]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[6]
KH-902	DM8VO16	Diabetic macular edema	9B71.02	Phase 3	[12]
ABP 938	DM00ACQ	Neovascular age-related macular degeneration	9B78.3Z	Phase 3	[13]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[14]
BAY-57-9352	DMVA5NS	Gastric adenocarcinoma	2B72	Phase 2	[15]
X-82	DMW1NKO	Age-related macular degeneration	9B75.0	Phase 2	[6]
Vorolanib	DMIM1U9	Non-small-cell lung cancer	2C25	Phase 2	[16]
BFH-772	DMVUX1C	Psoriasis vulgaris	EA90	Phase 2	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fibroblast growth factor-2 (FGF2)	TTGKIED	FGF2_HUMAN	Inhibitor	[2]
Vascular endothelial growth factor receptor (VEGFR)	TTVJ1D8	NOUNIPROTAC	Inhibitor	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011158)
• [2] US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions.
• [3] Assessment of sucralfate coating by sequential scintigraphic imaging in radiation-induced esophageal lesions. Gastrointest Endosc. 1995 Feb;41(2):109-14.
• [4] Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
• [5] DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Expression of fibroblast growth factor-2 transcripts in the healing of acetic acid-induced gastric ulcers. APMIS. 1999 Aug;107(8):767-72.
• [9] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [10] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [11] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [12] Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53.
• [13] Clinical pipeline report, company report or official report of Amgen
• [14] National Cancer Institute Drug Dictionary (drug id 452042).
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
• [17] CA patent application no. 841416, Method of selecting therapeutic indications.